Holen Sie sich die Stockscreener-App
227.54
0.21%
-0.49
Handel nachbörslich:
228.40
0.86
+0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$228.03
Offen:
$227
24-Stunden-Volumen:
3.72M
Relative Volume:
0.70
Marktkapitalisierung:
$401.96B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
108.29
EPS:
2.1013
Netto-Cashflow:
$18.24B
1W Leistung:
-1.66%
1M Leistung:
+3.14%
6M Leistung:
+18.30%
1J Leistung:
+19.96%
1-Tages-Spanne:
$224.31
$228.40
1-Wochen-Bereich:
$224.31
$232.16
52-Wochen-Spanne:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
227.54 | 402.83B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
820.10 | 740.84B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.93 | 458.49B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
123.43 | 250.00B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.03 | 219.80B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Clinical Overview, Companies, Therapeutic Assessment, Treatment Approaches, Pipeline Insights | AbbVie, Sanofi - Barchart.com
AbbVie: Deep Discount Before Earnings (NYSE:ABBV) - Seeking Alpha
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? - sharewise.com
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM - PR Newswire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Will AbbVie Inc. stock attract more institutional investorsEarnings Overview Summary & Capital Protection Trade Alerts - newser.com
Can AbbVie Inc. stock attract analyst upgrades2025 Year in Review & Risk Controlled Swing Trade Alerts - newser.com
Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest - Barchart.com
AbbVie Defends Challenge Of Colorado's Discount Drug Law - Law360
Can AbbVie Inc. stock withstand economic slowdownEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com
Will AbbVie Inc. (Common Stock) (4AB0) stock extend growth storyPortfolio Gains Report & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará
Can AbbVie Inc. stock surprise markets with earningsPortfolio Growth Summary & Real-Time Chart Pattern Alerts - newser.com
What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView
Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com
Is AbbVie Inc. stock a buy on dips2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Is AbbVie Inc. stock resilient to inflationJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Ophthalmic Drugs Market Set for Dynamic Growth with Key Players Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG - openPR.com
Fish Skin Disease Market to Witness Remarkable Growth With GSK - openPR.com
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 20252025 Top Gainers & High Yield Stock Recommendations - newser.com
How AbbVie Inc. stock performs in rising dollar environmentWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
How sentiment analysis helps forecast AbbVie Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com
Why AbbVie Inc. (4AB) stock stays on top picksPortfolio Risk Summary & Technical Pattern Alert System - newser.com
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance
AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com
AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism - ts2.tech
Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener
United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio - Yahoo Finance
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressureEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey
Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative - Yahoo Finance
AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):